Clinical Trial Detail

NCT ID NCT03085719
Title Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.